Advertisement

Ads Placeholder
Loading...

Diagnostic Medical Systems S.A.

DGM.PAEURONEXT
Healthcare
Medical - Devices
1.20
0.00(0.00%)
U.S. Market opens in 7h 38m

Diagnostic Medical Systems S.A. Fundamental Analysis

Diagnostic Medical Systems S.A. (DGM.PA) shows weak financial fundamentals with a PE ratio of -7.49, profit margin of -6.29%, and ROE of -23.00%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.09

Areas of Concern

ROE-23.00%
Operating Margin-0.75%
We analyze DGM.PA's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -21.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-21.1/100

We analyze DGM.PA's fundamental strength across five key dimensions:

Efficiency Score

Weak

DGM.PA struggles to generate sufficient returns from assets.

ROA > 10%
-5.38%

Valuation Score

Excellent

DGM.PA trades at attractive valuation levels.

PE < 25
-7.49
PEG Ratio < 2
-0.09

Growth Score

Weak

DGM.PA faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

DGM.PA shows balanced financial health with some risks.

Debt/Equity < 1
1.56
Current Ratio > 1
1.29

Profitability Score

Weak

DGM.PA struggles to sustain strong margins.

ROE > 15%
-2299.85%
Net Margin ≥ 15%
-6.29%
Positive Free Cash Flow
N/A

Key Financial Metrics

Is DGM.PA Expensive or Cheap?

P/E Ratio

DGM.PA trades at -7.49 times earnings. This suggests potential undervaluation.

-7.49

PEG Ratio

When adjusting for growth, DGM.PA's PEG of -0.09 indicates potential undervaluation.

-0.09

Price to Book

The market values Diagnostic Medical Systems S.A. at 1.69 times its book value. This may indicate undervaluation.

1.69

EV/EBITDA

Enterprise value stands at 73.67 times EBITDA. This signals the market has high growth expectations.

73.67

How Well Does DGM.PA Make Money?

Net Profit Margin

For every $100 in sales, Diagnostic Medical Systems S.A. keeps $-6.29 as profit after all expenses.

-6.29%

Operating Margin

Core operations generate -0.75 in profit for every $100 in revenue, before interest and taxes.

-0.75%

ROE

Management delivers $-23.00 in profit for every $100 of shareholder equity.

-23.00%

ROA

Diagnostic Medical Systems S.A. generates $-5.38 in profit for every $100 in assets, demonstrating efficient asset deployment.

-5.38%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-7.49

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.09

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.69

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.56

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.29

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.23

vs 25 benchmark

ROA

Return on assets percentage

-0.05

vs 25 benchmark

ROCE

Return on capital employed

-0.01

vs 25 benchmark

How DGM.PA Stacks Against Its Sector Peers

MetricDGM.PA ValueSector AveragePerformance
P/E Ratio-7.4928.54 Better (Cheaper)
ROE-23.00%738.00% Weak
Net Margin-6.29%-43982.00% (disorted) Weak
Debt/Equity1.560.34 Weak (High Leverage)
Current Ratio1.292806.01 Neutral
ROA-5.38%-14624.00% (disorted) Weak

DGM.PA outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Diagnostic Medical Systems S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ